Form 4: Corcept Therapeutics CFO Atabak Mokari Reports Share Transactions

Corcept Therapeutics' Chief Financial Officer, Atabak Mokari, reported the acquisition and disposal of company shares on December 2, 2024, including shares withheld for tax obligations and shares purchased under a company plan.

Summary

• Atabak Mokari, the Chief Financial Officer of Corcept Therapeutics, filed a Form 4 detailing changes in his beneficial ownership of company stock.
• On December 2, 2024, Mr. Mokari had 182 shares withheld to cover tax obligations related to vesting restricted stock units at a price of $57.68 per share.
• He also acquired 231 shares through a company purchase plan at a price of $59.21 per share.
• Additionally, 231 shares were granted as unvested restricted stock awards under the same purchase plan at no cost.
• Following these transactions, Mr. Mokari's total direct holdings increased to 12,798 shares, including unvested restricted stock awards.

Sentiment

Score: 7

Explanation: The document reflects routine insider transactions, which are neither particularly positive nor negative. The purchase of shares by the CFO is a slightly positive signal.

Positives

• The purchase of 231 shares by the CFO at $59.21 per share indicates confidence in the company's future.
• The grant of 231 unvested restricted stock awards aligns the CFO's interests with the long-term performance of the company.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the trading activities of company executives.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, ensuring transparency of insider trading.
• The transactions reported are typical for executives who receive stock-based compensation and participate in company purchase plans.
• Similar filings are made by executives at comparable companies such as Exelixis (EXEL) and Halozyme Therapeutics (HALO).

Stakeholder Impact

• The transactions provide transparency to shareholders regarding the CFO's stock ownership.
• The CFO's purchase of shares may be viewed positively by investors.

Key Dates

Keywords

Corcept Therapeutics, CORT, Atabak Mokari, Form 4, insider trading, stock transaction, restricted stock units, share purchase plan, beneficial ownership